Skip to main
INGN
INGN logo

Inogen (INGN) Stock Forecast & Price Target

Inogen (INGN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Inogen Inc. is strategically positioning itself for growth by enhancing synergies across various sales channels, revitalizing its direct-to-consumer approach, and strengthening business-to-business relationships, thereby expanding its market reach. The partnership with Yuwell for entry into the Chinese COPD market presents substantial long-term growth opportunities, as this market is approximately ten times larger than that of the United States. Additionally, the projected growth of portable oxygen concentrators (POCs) to account for 58% of the market within the next five years indicates a favorable trend that could significantly benefit Inogen's revenue prospects.

Bears say

Inogen Inc has faced significant challenges due to an oversized sales force that led to unprofitable operations, despite prior revenue growth. The company reported a 17% decline in B2B sales and a 28% decline in DTC sales in 2023, indicating a severe downturn in its sales channels. Additionally, the shift from higher-paying Medicare to lower-reimbursing private insurance and an increasing number of capped patients is further exacerbating the revenue decline, contributing to a negative outlook for the company's financial performance.

Inogen (INGN) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inogen (INGN) Forecast

Analysts have given Inogen (INGN) a Buy based on their latest research and market trends.

According to 3 analysts, Inogen (INGN) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inogen (INGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.